Feb 16 (Reuters) - Kalytera Therapeutics Inc KALY.V :
* Kalytera Therapeutics to announce phase 2A clinical study results investigating cbd for the treatment of acute graft versus host disease Source text for Eikon: ID:nGNXNQFSLa Further company coverage: KALY.V